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Phycocyanin (PC), a photosynthetic pigment produced by cyanobacteria has been gained attention due to its distinct 
properties such as antioxidant and anti-proliferative. Acute and sub acute toxicity studies were carried out to determine the 
biocompatibility of the extracted phycocyanin on Wistar rat model. PC was extracted from Spirulina platensis biomass by 
cold maceration followed by successive purification by ammonium sulphate precipitation and gel filtration chromatography. 
Biocompatibility of the purified phycocyanin was carried out by acute toxicity studies using Wistar rat model. Acute toxicity 
has been determined by the effect of single oral dose of PC with two different concentrations (250 and 500 mg/Kg) on the 
body weight, general behaviour, and mortality. In sub-acute treatment. The effect of phycocyanin on the various parameters 
at the respective concentration as single oral dose daily during 28 days was studied. Cold maceration followed by 
maceration brought about food grade phycocyanin C (C-PC) which final yield and purity were increased in the successive 
purification steps. Antioxidative study using DPPH assay reveals the effective free scavenging activity of the phycocynin as 
concentration-dependent manner. Biocompatibility studies against Wister rat model did not exhibit any harmful effect. Any 
sign of toxic effect on biochemical, hematological and histopathological parameters was not observed in all the tested 
animals of treatment groups during the study period which reveals a high level of biocompatibility. The present study 
suggests the possible utilization of phycocyanin C as an effective pharmaceutical agent. 
Keywords: Acute Toxicity, Antioxidant, Biocompatibility, Phycocyanin, Pigment, Spirulina platensis, Wistar model 
Oxidative stress is an important factor in the 
formation of diverse life-threatening diseases, from 
cancer to cardiovascular and degenerative diseases
1-3
. 
In order to protect the body against the consequences 
of oxidative stress, an efficacious approach has been 
improving in antioxidant nutrition. In this regard, 
scientific studies have shown that antioxidants from 
natural sources have higher bioavailability and 
therefore higher protective efficacy
4,5
. Recent studies 
have reported that natural products including plants, 
animals, and microorganism have been the basis of 
treatment of various oxidative stress-mediated 
diseases. Among the sources, algae and algae-based 
products have gained recent attention due to their high 
efficacy and best biocompatibility
6
. 
Phycocyanin C (PC) is a water-soluble, highly 
fluorescent protein derived from cyanobacteria has a lot 
of application as food colouring agents, cosmetics, and 
biomedical research
7,8
. Antioxidant, radical scavenging, 
anti-inflammatory, anti-cancer, anti-tumour properties 
of PCs extracted from Spirulina has been 
experimentally proved under laboratory and animal 
model studies
9-14
. Experimental recent studies reveals 
phycocyanin from Spirulina enhanced curative red 
blood cells production and immunity in animal model 
studies
15,17
. Phycobiliproteins are widely used in 
laboratory tests and immunological assays, due to 
their properties such as high fluorescence, good 
storage stability at temperatures between 4 to 10C, 
isoelectric point (IP) close to 4.65, making them 
easily linkable to antibodies and other proteins by 
conventional techniques without changing its spectral 
characteristics. It has a high molar absorbance 
coefficient and emission, oligomeric stability and high 
photo-stability
18-20
. PCs can be used for the detection 
of multiple myeloma cells and as a potential 
therapeutic agent in oxidative stress- induced 
disease
21
. 
Because of the potential application of 
phycocyanin in biotechnology and biomedicine, it is 
mandatory to determine toxicity assessment tests 
————— 
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under in vitro and in vivo condition using standard 
methods. Unlike in vitro toxicity studies, in vivo 
testing is highly preferred to determine the 
biocompatibility. In order to establish the safety of 
phycocyanin C, acute and sub-acute toxicity studies 
using a suitable animal model is essential. The types 
of toxicity tests which are routinely performed by 
pharmaceutical manufacturers in the investigation of a 
new drug involve acute, sub-acute and chronic 
toxicity. Determination of acute oral toxicity is 
usually an initial screening step in the assessment and 
evaluation of the toxic characteristics of all 
compounds
22,23
. In the present work, Wistar rats were 
selected for studying the acute and sub-acute toxicity 
of phycocyanin. There are various distinct characters 
of Wistar rat like physiological, metabolic pathways, 
anatomical similarities with human, easy 
maintenance, short life period would suggest the 
possible utilization in toxicity studies. Evaluation of 
toxicity of phycocyanin under in vivo system using 
Wistar rat model studied in the present investigation 
is helpful to confirm biocompatibility and its possible 
utilization of Spirulina mediated PC as an effective 
and safe nutraceutical agent.  
 
Materials and Methods 
 
Algal strain  
Extraction of phycocyanin was derived from 
biomass of laboratory stock culture of Spirulina 
platensis cultivated in BG 11 growth media. Biomass 
thus obtained after the incubation period of growth 
was collected and used for further studies. 
 
Extraction and purification 
Extraction of phycocyanin from Spirulina platensis 
was carried out by cold maceration method followed 
by sonication
24
. In this method, known quantity of 
algal biomass which previously dried at 40°C for 12 h 
was immersed in 100 mL of phosphate buffered saline 
(pH 7.4) followed by sonication for 2 h. After 
sonication, the suspension was subjected to freezing 
at −80°C for 24 h, thawed to room temperature. 
Centrifugation of the thawed suspension was done at 
12000 rpm for 10 min 2 times. Supernatant thus 
obtained was collected and used as the source of 
crude phycocyanin and subjected to purification by 
different methods. Different concentration of 
ammonium sulphate (25 and 50%) was added to the 
collected supernatant with continuous stirring. The 
resulting suspension was centrifuged at 12000 rpm for 
30 min and the collected pellet was re-suspended in 
0.1 M Tris-HCl buffer followed by dialysis. Dialysis 
was done using dialysis membrane (Hi-media, India) 
with the molecular weight cut off l KD. The dialysed 
material was subjected to column chromatography 
separation using 10 mM phosphate buffer  
pre-equilibrated Sephadex G 25 column followed by 
elution with 10 mM phosphate buffer. Eluents thus, 
obtained was lyophilized and used for further studies. 
Characterization of the lyophilized samples was done 
by UV visible spectroscopy using Shimadzu-1800 
spectrophotometer (800-200 nm range) and FTIR 
analysis. Lyophilized samples were pelletized with 
KBr and the pelletized spectrum was recorded in the 
range of 4000-500 cm
−1
 (Bruker Optic GmbH 
Tensor). 
 
Antioxidative activity 
Antioxidative activity of the purified phycocyanin 
was done by DPPH free radical assay Shiban et al.
25
. 
 
Biocompatibility assessment using wistar rat model 
 
Test animal selection and maintenance 
Biocompatibility assessment of extracted 
phycocyanin was studied by determination of acute 
and sub acute toxicity using Wistar rat model 
according to the guidelines of the Committee for the 
Purpose of Control and Supervision of Experiments 
on Rats (CPCSEA) and the protocol was approved by 
the Institutional Animal Ethics Committee (IAEC No: 
KMCRET). Healthy male and female Wistar rats 
were procured from Sri Venkateshwara Enterprises 
Private Limited, Bangalore, India. Selected animals 
were maintained in an air conditioned room at 26°C, 
35% of relative humidity with 12 h dark cycle. 
Polypropylene cages were used for housing of the 
animals with rice husks for bedding andnormal rat 
chow as feed (procured from Sai Durga animal Feed, 
Bangalore, India) followed by acclimatization for ten 
days in the environment prior to experiment. 
 
Experimental design 
Test animals were divided into three groups and 
each group consisting of six animals. Group-I 
Control, group II group III were Phycocyanin C 
treatment categories. Group I received saline, group II 
and group III received 250 mg/Kg and 500 mg/Kg of 
phycocyanin C, respectively. Freeze dried form of PC 
was added in distilled water and completely dissolved 
for oral administration. The dose was prepared of a 
required concentration before dosing by dissolving 
PC in distilled water. Phycocyanin was administered 
orally to each rat as single dose using a needle fitted 
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on to a disposable syringe of appropriate size at the 
following different doses. The concentration was 
adjusted according to its body weight. The volume 
was not exceeding 10 mL/Kg body weight. 
Variability in test volume was minimized by adjusting 
the concentration to ensure a constant volume at all 
dose levels. 
After administration, the treated animals were 
observed at least twice daily with the purpose of 
recording any symptoms of ill health or behavioural 
changes. Clinical signs of toxicity for 28 days. 
Prior to the beginning of treatment and daily, the 
food intake of each cage was recorded for the period 
of 28 days and the mean weekly intake per rats was 
calculated. In addition, the water consumption in each 
cage was measured daily for a period of 28 days. 
 
Body weight 
The body weight of each rat was recorded one week 
before the start of treatment and during the course of 
the treatment on the day of initial, 3
rd
, 7
th
, 10
th
, 14
th
, 
17
th
, 20
th
, 24
th
, and 28
th
 days (day of sacrifice). The 
mean weights for the different groups and sexes were 
calculated from the individual weights. 
 
Hematological and biochemical parameters 
 
Blood collection  
Blood was collected through retro-orbital sinus 
from all the animals of different groups on the 28
th
 
day. Animals were fasted overnight prior to the blood 
collection and the blood was collected in tubes 
containing Heparin/EDTA as an anticoagulant.  
During the 4
th 
week of treatment, samples of blood 
were withdrawn from the orbital sinus of 6 males from 
each group, under light ether anesthesia after fasting 
for 16 h. The blood samples are used to evaluate 
hematological parameters like hemoglobin (g/L), PCV 
(Packed cell volume), white blood corpuscles 
(×10
3
/cmm), red blood corpuscles (×10
3
/cmm), blood 
plateletcount, lymphocytes, (×10
3
/cmm), neutrophils 
(%), monocytes, eosinophils, mean platelet volume 
using auto analyser (Bio-Rad).  
 
Biochemical parameters 
The collected blood samples were centrifuged at 
10000 g for 10 min to separate the serum. The 
separated serum used to evaluate biochemical 
parameters like total cholesterol, triglycerides, high 
density lipoprotein (HDL), total bilirubin (direct & in 
direct), SGOT, SGPT, alkaline phosphatase, creatinine, 
urea, and uric acid using full automated biochemical 
analyser (Bio Rod). 
Terminal studies  
 
Sacrifice and macroscopic examination 
On completion of the 4 weeks of treatment, Wistar 
rats were sacrificed by ether inhalation. A full autopsy 
was performed on all animals which included an 
examination of the external surface of the body, all 
orifices, cranial, thoracic and abdominal cavities, and 
their contents both in situ and after evisceration. As the 
number of animals exceeded the number that could be 
sacrificed in one day, the autopsies were carried out 
over three consecutive days at the end of the treatment 
period.  
 
Organ weights 
After the macroscopic examination, the following 
organs were weighed after separating the superficial 
fat: brain, heart, spleen, kidneys, testes, liver, lungs, 
pancreas and stomach. 
 
Histopathological examination 
The tissues from the respective group of sacrificed 
animals were immediately fixed in 10% buffered 
neutral formalin solution. The tissue embedded in 
molten paraffin with the help of metallic blocks, 
covered with flexible plastic moulds and kept under 
freezing plates to allow the paraffin to solidify. Cross 
sections (5 µm thick) of the fixed tissue were cut using 
microtome (Leica PM 2125, Germany). These sections 
were then stained with hematoxylin and eosin method
26
 
and visualized under a light microscope (Magnus, 
India) to study the microscopic architecture. 
 
Results 
 
Isolation of PC 
Phycocyanin was isolated from Spirulina platensis 
algal biomass by cold maceration followed by 
sonication followed by successive purification 
methods. Figure 1 shows the extracted phycocyanin 
 
 
Fig. 1 — Extracted phycocyanin 
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with bright blue color water-soluble pigment (Fig. 1). 
The purity of phycocyanin was found to increase in  
25 and 50% ammonium sulphate precipitation. Final 
yield and purity were increased in the column 
chromatography using Sephadex G-25 column (Fig. 2). 
Purified phycocyanin fractions thus obtained was 
characterized by UV-vis spectroscopy and FTIR which 
reveals the high rate purity of extracted C-PC by 
showing maximum absorbance at 280/620 nm using a 
Shimadzu UV-2401 spectrophotometer Lyophilized PC 
thus obtained reveals A620/A280 ratio greater than 0.7, 
which is considered as food grade (Fig. 3), characteristic 
absorption peaks at specific wave number coincided 
with those expected for the peptide. (Fig. 4). 
 
Antioxidative activity 
Antioxidative activity was studied by DPPH 
method. The DPPH scavenging activity has been 
commonly used to detect the antioxidant activity of 
different samples sources, due to its sensitivity to 
lower concentrations of active standards from natural 
sources. The steady radical, DPPH, has a maximum 
absorbance at 517 nm and could swiftly undergo 
scavenging by antioxidants. Complex free radical 
scavenging activities of samples are indicated by 
lower absorbance at 517 nm. It was found that the 
highest concentration of PC at 100 μg/mL and  
75 μg/mL had the highest percentage of antioxidant 
activity (Fig. 5). 
 
Acute and sub-acute toxicity studies 
Biocompatibility assessment of PC was carried out 
on Wistar rat models which was confirmed by 
changes in the various parameters of the tested animal 
groups. In this toxicity study, the rats were treated 
with two concentration of phycocyanin as 250 and 
500 mg/Kg which did not exhibit any signs of 
toxicity, behavioural changes, and mortality in the test 
groups when observed during 28 days of the acute 
toxicity experimental period. No major sign of 
changes in behaviour and mortality was observed in 
all the groups which show the administrated 
phycocyanin seems to be safe at a dose level of  
250 and 500 mg/Kg. Any pharmaceutical drug or 
compound with a higher than 100 mg/Kg could be 
considered safe and low toxic
31
.This suggests that the 
administrated phycocyanin is nontoxic in the single 
oral dose of 250 and 500 mg/Kg. Phycocyanin at both 
dosages did not induce any toxic effect on organ 
weight, biochemical, hematological parameters after 
the 28 days of treatment.  
 
 
Fig. 2 — Effect of purification methods on the purity and final yield 
of phycocyanin 
 
 
Fig. 3 — UV- Spectra of isolated phycocyanin 
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Study on the body weight was studied one week 
before the start of treatment, and during the course of the 
treatment Distinct effect on the body weight of tested 
animals of both sexes at all the tested time periods was 
not recorded inboth dosages of phycocyanin treatment 
(Table 1). The absence of a significant difference inthe 
weight of vital organsas presented in table provides 
support for the safety of phycocyanin. Acute toxicity test 
revealed phycocyanin at the both tested concentration 
was found to non-toxic. No mortality was observed 
during the whole experiment. During the dosing period 
and in the last day, the quantity of food and water intake 
by different dose groups was found to be comparable 
with the control group. No abnormal deviations were 
observed. No significant changes were observed in the 
values of different parameters studied when compared 
with controls and values obtained were within normal 
laboratory limits. 
Effect of phycocyanin on hematological parameters 
were studied using the auto analyser. There were no 
significant changes were observed in hemoglobin 
(Hb), red blood cell (RBC), white blood cell (WBC), 
packed cell volume (PCV), Erythrocyte sedimentation 
rate (ESR) in all the treated groups as compared to 
respective control groups (Table 2). There was no 
significant changes were recorded in biochemical 
parameters of the animal groups (Table 3). Alkaline 
phosphatise, bilirubin, total cholesterol, creatinine, 
urea, SGPT, and SGOT level were not significantly 
varied in the test groups  
Histopathological examination of the tissue section 
was   also   supported  biocompatibility   tissue  section 
Table 1 — Effect of sub-acute doses (28 days) of phycocyanin  
C on organ weight (physical parameters) 
Organ Control Dose  
(250 mg/Kg) 
Dose  
(500 mg/Kg) 
Brain 1.805 ± 0.181 1.770 ± 0.166 1.952 ± 0.144 
Heart 0.900 ± 0.113 0.851 ± 0.052 0.950 ± 0.145 
Kidney left 0.701 ± 0.044 0.754 ± 0.109 0.830 ± 0.091a 
Kidney right 0.692 ± 0.096 0.713 ± 0.086 0.817 ± 0.096 
Liver 5.766 ± 0.787 6.306 ± 1.325 6.674 ± 0.394 
Lungs 1.495 ± 0.263 1.369 ± 0.214 2.015 ± 0.390a 
Spleen 0.951±0.286 0.779 ± 0.214 0.904 ± 0.202 
Values are expressed as the mean±SD; Statistical significance (P) 
calculated by one way ANOVA followed by Dennett’s 
aP< 0.05 calculated by comparing treated group with control group. 
 
 
 
Fig. 4 — FTIR spectra of phycocyanin 
 
 
 
Fig. 5 — Antioxidant activity (%) of phycocyanin 
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derived from various organs were examined using 
standard methods. Phycocyanin treatment shows no 
significant pathology. Tissue sections of heart, lungs, 
liver, stomach, kidneys, uterus and testis reveal the 
complete absence of tissue damage at both the 
dosages tested (Fig. 6). Histopathological examination 
of heart tissue of both the dosages of phycocyanin 
treatment group exhibited no morphological changes 
in myocardium. As in the control group, there is mild 
edema, focal lymphocytic infiltrates in the stroma. 
There is no loss of striations or myocyte degeneration 
or inflammations. Both group I and group II of lungs 
tissue shows normal alveoli, bronchi, and bronchioles. 
Blood vessels show congestion and there is mild 
inflammatory seen in the interstitium. There is no 
inflammatory infiltrates seen in the alveoli. The 
Normal lobular architecture was observed in liver 
tissue of control and phycocyanin treatment groups. 
Hepatocytes of both control and treatment groups 
show no significant pathology. Portal traid shows bile 
duct hyperplasia and mild periportal infiltration. 
Central vein  shows mild  congestion. Sinusoids show  
Table 2 — Effect of phycocyanin C on the haematological parameters 
Haematological parameters 500 mg/Kg 
Female 
500 mg/Kg 
Male 
250 mg/Kg 
Female 
250 mg/Kg 
Male 
Control 
Female 
Control 
Male 
Total RBC count  
(1 × 106 mm3) 
6.19 ± 0.012c 6.18 ± 0.231c 4.18 ± 0.162 5.00 ± 1.016 4.55 ± 0.404 4.33 ± 0.150 
Total WBC count  
(1 × 103 mm3) 
11.10 ± 1.270b 12.90 ± 1.501 9.50 ± 0.346c 12.35 ± 2.483 15.00 ± 0.924 13.60 ± 0.577 
Haemoglobin (g/L) 17.30 ± 1.270a 17.00 ± 1.848a 11.70 ± 0.693b 14.00 ± 0.693 14.85 ± 0.520 14.40 ± 0.462 
Lymphocytes (%) 89.50 ± 0.577 87.00 ± 3.464 75.50 ± 0.577c 89.00 ± 3.464 91.00 ± 1.155 90.50 ± 0.577 
Mean corpuscular haemoglobin 
(Picograms/cell) 
20.50 ± 0.577a 21.55 ± 0.173c 19.35 ± 0.289 19.95 ± 0.173 19.35 ± 0.866 17.90 ± 0.693a 
Monocytes (%) 3.50 ± 0.577 4.00 ± 2.309 2.50 ± 0.577 2.50 ± 0.577 2.00 ± 1.155 1.50 ± 0.577 
Packed cell volume (%) 45.85 ± 5.485 47.30 ± 5.543 33.65 ± 1.790c 43.70 ± 2.540 46.10 ± 0.231 44.45 ± 2.714 
Eosinophils (%) 4.50 ± 0.577b 5.00 ± 1.155c 3.50 ± 0.577 4.50 ± 0.577b 2.50 ± 0.577 2.00 ± 0.000 
Polymorphs (%) 2.50 ± 0.577 4.00 ± 0.000 14.50 ± 4.041c 4.00 ± 2.309 4.50 ± 1.732 4.50 ± 0.577 
Values are expressed as the mean±SD; Statistical significance (P) calculated by one way ANOVA followed by Dennett’s aP< 0.05 
calculated by comparing treated group with control group. 
 
Table 3 — Effect of phycocyanin C on biochemical parameters 
Biochemical 
parameter 
500 mg/Kg 
Female 
500 mg/Kg 
Male 
250 mg/Kg 
Female 
250 mg/Kg 
Male 
Control 
Female 
Control 
Male 
Total cholesterol (mg/dL) 94.35 ± 5.600c 138.40 ± 5.543c 109.90 ± 0.346b 128.90 ± 4.157a 120.50 ± 2.656 98.80 ± 0.462c 
Triglycerides (TG) (mg/dL) 123.80 ± 17.782c 295.90 ± 11.316c 151.05 ± 6.755b 311.20 ± 4.157c 199.90 ± 31.639 124.45 ± 0.981c 
High Density Lipoprotein 
(HDL) (mg/dL) 
46.20 ± 1.155b 56.60 ± 7.275 70.00 ± 2.656 56.00 ± 8.198 60.65 ± 5.023 63.95 ± 0.635 
Bilirubin Total (mg/dL) 0.55 ± 0.058b 0.95 ± 0.035 0.98 ± 0.029 0.85 ± 0.404 1.05 ± 0.058 0.85 ± 0.058 
Bilirubin Direct (mg/L) 0.16 ± 0.023 0.19 ± 0.012 0.17 ± 0.023 0.20 ± 0.115 0.22 ± 0.023 0.15 ± 0.006 
Bilirubin In direct (mg/L) 0.43 ± 0.081b 0.85 ± 0.150 0.85 ± 0.058 0.65 ± 0.289 0.85 ± 0.058 0.61 ± 0.052 
SGOT(U/L) 47.25 ± 1.212b 60.90 ± 5.196 67.80 ± 0.462 59.30 ± 18.591 76.50 ± 11.201 44.75 ± 0.173c 
SGPT(U/L) 39.00 ± 1.386 49.60 ± 11.432b 49.95 ± 0.404b 41.30 ± 5.196 30.65 ± 10.104 28.55 ± 1.212 
ALP(U/L) 259.40 ± 3.464 306.00 ± 30.600 277.95 ± 1.328 297.90 ± 9.930 278.30 ± 16.166 198.80 ± 2.771c 
Creatinine (mg/dL) 0.65 ± 0.058 0.75 ± 0.058 0.75 ± 0.173 0.65 ± 0.173 0.60 ± 0.000 0.60 ± 0.115 
Urea(mg/dL) 18.80 ± 0.693 23.90 ± 0.577 21.75 ± 0.404 23.05 ± 8.025 21.55 ± 1.674 23.90 ± 1.848 
Uric acid (mg/dL) 4.25 ± 0.289a 5.45 ± 0.058 4.00 ± 0.924a 4.30 ± 0.577a 9.00 ± 4.388 5.50 ± 0.577 
Values are expressed as the mean±SD; Statistical significance (p) calculated by one way ANOVA followed by Dennett’s  
aP< 0.05 calculated by comparing treated group with control group. 
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mild dilatation. There is the presence of pan lobular 
inflammation composed of lymphocytes. Portal raid 
shows bile duct hyperplasia and mild periportal 
infiltration. Central vein and Sinusoids show mild 
dilatation.  
Toxic effect of phycocyanin on tissue morphology 
of stomach also revealed the best biocompatibility. 
Section studied from the stomach shows normal 
mucosa. Parietal cells and peptic cells are normal in 
number, distribution, and morphology. Muscularis 
propria and serosa show no significant pathology. 
There is no inflammation/granuloma seen in the section 
studied. The section from lower part of oesophagus 
shows no structural modification. A similar finding 
 
 
Fig 6 — (A) Histopathological examination of Group I (Control); (B) Histopathological examination of Group II (Phycocyanin  
250 mg/Kg) treated animals; and (C) Histopathological examination ofGroup III (Phycocyanin C 500 mg/Kg) treated animals 
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was also observed in both dosages of phycocyanin 
treated animals. There is no distinct histopathological 
effect was recorded in the treatment group. Normal 
morphological structure of the kidney was not affected 
in treatment groups. As in the control group, section 
studied from the kidney shows both cortex and 
medulla. The glomeruli show normal morphology. 
Both the tubules are histologically normal. The 
interstitium shows focal dense lymphocytic in filtrates. 
Blood vessels show congestion. 
Biocompatibility of phycocyanin was also 
confirmed by no significant histopathic effect on the 
uterus. Uterus tissue sections of control and treatment 
groups illustrate the normal morphology of uterus 
tissue. Section studied from the uterus with cervix 
shows chronic cervicitis, various stages of ovarian 
follicle having fluid accumulation in the centre of the 
follicle (follicular antrum) showing normal 
development. The fallopian tube also shows normal 
development. Nontoxic effect of phycocyanin 
treatment is also supported by the complete absence of 
histological effect of both the dosages of phycocyanin 
on the testis. Both control and treatment demonstrated 
normal seminiferous tubules which confirm the normal 
spermatogenesis. There is no maturation arrest/atrophy 
seen. 
 
Discussion 
Cyanobacterial phycocyanin (PC) is one of the 
major light-harvesting biliproteins of Cyanobacteria 
and is of great importance because of its various 
biological and pharmacological properties. The 
success of phycocyanin isolation from Spirulina dry 
powder is primarily based on extraction procedure. 
Cold maceration is one of the best methods of 
extraction of PC from cyanaobacterial species. In this 
study, cold maceration method (using water and 0.1 
M sodium phosphate buffer, pH 7.0) followed by 
sonication method was used which yield high stable 
phycocyanin
24
. Extracted phycocyanin was further 
purified by various purification techniques like 
ammonium sulphate precipitation, dialysis and 
column chromatography separation. For purifying 
phycocyanin, various precipitating agents are used. 
Ammonium sulphate is the widely used precipitating 
agent because of its high rate of precipitation which 
used to obtain high enriched phycocyanin in the 
extracted suspension and easier availability
27-30
. In the 
present study, enrichment of PC in the extracted 
solution was found be increased in ammonium 
sulphate precipitation and further increase in purity 
and yield of was recorded in successive purification 
steps. Antioxidative activity of purified phycocyanin 
was studied by DPPH assay which reveals tested 
phycocyanin brought about a high rate of free radical 
scavenging activity. 
 
Biocompatibility of extracted phycocyanin was 
studied on Wister rat model by determination of 
behavioural changes, mortality, body weight, 
hematological, biochemical and histopathological 
parameters of rat model administrated with different 
dosages of PC. The present study clearly reveals a 
single oral dose of the phycocyanin showed no 
mortality and no changes in the body, organ weight of 
these rats even under higher dosage levels. Scientific 
reports indicate that decrease or increase in the body or 
organ weight is due to drug-mediated physiological 
stress
32
. These results showed that high margin of 
safety of the phycocyanin. Hematological and 
biochemical parameters also recorded no distinct 
effects on the treatment groups. Reports suggest that 
the bone marrow is responsible for the production of 
the blood cell and drugs derived from various sources 
have to affect red blood cell level
33
. In this study, the 
tested phycocyanin may not have harmful effects on 
bone marrow function and justify the fact that at all 
doses ofphycocyanin does not induce anemia and 
immune suppressive state making it safe. Many studies 
have confirmed that elevated serum levels of hepatic 
enzymes, transaminases (SGPT and SGOT) are not a 
directly linked for liver injury but increase levels are 
responsible to cause inflammation, cellular leakage and 
damage of cell membrane to cells in the liver
34,35
. 
Antioxidative enzymes are the major defense barriers 
which gives protection against oxidative cell 
damages
36
. The main target organ for drug or bioactive 
active compound is liver where exposed to the foreign 
substances being absorbed in intestines and 
metabolized to other compounds which may or may 
not be hepatotoxic to the mice
37
. Phycocyanin 
treatment did not show any significant rise in hepatic 
enzymes which suggests the best biocompatibility of 
the phycocyanin. Histopathological study also 
supported non-toxic effect of phycocyanin by showing 
no changes in the tissue morphology of all the tested 
tissues derived from organs. Nutraceutical therapy 
values of dietary proteins from the fresh water  
mussel Lamellidens marginalis (Lam.) reported by 
Haldar et al.
38
 reveals the functional properties of 
bioactive peptides as in C-Phycocyanin a bioactive 
peptide from fresh water algae. 
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Conclusion 
Phycocyanin extracted from Spirulina platensis by 
cold maceration followed by successive purification 
brought about food grade phycocyanin C. It seems that 
PC exhibited less toxicity under in vivo studies. There 
was no obvious toxicity with the treatment of PC on 
the tested rat animal model. It was found to be safe 
nutraceutical and antioxidative agent. Further study 
helps to optimize the conditions for the enhanced 
production of phycocyanin and its utilization as the 
nutraceutical agent in the human trails.  
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